Literature DB >> 17268271

The impact of methylprednisolone on lesion severity following spinal cord injury.

Bradley G Leypold1, Adam E Flanders, Eric D Schwartz, Anthony S Burns.   

Abstract

STUDY
DESIGN: Retrospective study comparing spinal cord injury (SCI) lesion characteristics in methylprednisolone (MPS) treated versus untreated patients as demonstrated by magnetic resonance (MR) imaging.
OBJECTIVE: Determine if the administration of MPS immediately following SCI affects lesion severity. SUMMARY OF BACKGROUND DATA: The administration of MPS in the setting of acute SCI has become controversial. Since magnetic resonance imaging (MRI) is sensitive for the detection of spinal cord edema and hemorrhage, changes in lesion characteristics would support a biologic effect due to MPS.
METHODS: Patients with cervical spinal injury treated with the recommended dose of methylprednisolone (bolus 30 mg/kg + 5.4 mg/kg per hour over 24 hours) initiated within 8 hours of injury were compared to historical controls that did not receive steroids. All patients (n = 82) sustained clinically complete SCI (ASIA Grade A) and underwent MRI on the same 1.5 Tesla unit. The length of spinal cord edema, presence/absence of intramedullary hemorrhage, and length of intramedullary hemorrhage were measured on T2-weighted and gradient echo MR images. Comparisons of lesion severity were then made between untreated and treated subjects.
RESULTS: Forty-eight of 82 patients with complete injuries received MPS therapy. After accounting for differences in the mean age of the treatment and control groups, multiple regression analysis demonstrated a persistent reduction in the mean length of intramedullary hemorrhage, 2.6 U in the treatment group versus 4.4 U in the control group (P = 0.04). Although there was a reduction in the number of patients exhibiting spinal cord hemorrhage in the treated group compared with the untreated group (65% vs. 91%), this result was not statistically significant (P = 0.16). There was no statistically significant effect of MPS treatment on the mean length of the spinal cord edema between treated versus untreated subjects (10.3 vs. 12.0, respectively, P = 0.85).
CONCLUSIONS: MRI suggests MPS therapy in the acute phase of spinal cord injury may decrease the extent of intramedullary spinal cord hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268271     DOI: 10.1097/01.brs.0000253964.10701.00

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  8 in total

Review 1.  Remote cell death in the cerebellar system.

Authors:  M T Viscomi; F Florenzano; L Latini; M Molinari
Journal:  Cerebellum       Date:  2009-04-22       Impact factor: 3.847

Review 2.  The role of magnetic resonance imaging in the management of acute spinal cord injury.

Authors:  Anthony Bozzo; Judith Marcoux; Mohan Radhakrishna; Julie Pelletier; Benoit Goulet
Journal:  J Neurotrauma       Date:  2010-08-30       Impact factor: 5.269

3.  Agathisflavone as a Single Therapy or in Association With Mesenchymal Stem Cells Improves Tissue Repair in a Spinal Cord Injury Model in Rats.

Authors:  Ravena P do Nascimento; Lívia B de Jesus; Markley S Oliveira-Junior; Aurea M Almeida; Eduardo L T Moreira; Bruno D Paredes; Jorge M David; Bruno S F Souza; Maria de Fátima D Costa; Arthur M Butt; Victor Diogenes A Silva; Silvia L Costa
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

4.  The effect of preexisting hypertension on early neurologic results of patients with an acute spinal cord injury.

Authors:  C K Kepler; G D Schroeder; N D Martin; A R Vaccaro; M Cohen; M S Weinstein
Journal:  Spinal Cord       Date:  2015-04-28       Impact factor: 2.772

5.  The early evolution of spinal cord lesions on MR imaging following traumatic spinal cord injury.

Authors:  B G Leypold; A E Flanders; A S Burns
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-22       Impact factor: 3.825

6.  Proteomic Analysis of the Spatio-temporal Based Molecular Kinetics of Acute Spinal Cord Injury Identifies a Time- and Segment-specific Window for Effective Tissue Repair.

Authors:  Stephanie Devaux; Dasa Cizkova; Jusal Quanico; Julien Franck; Serge Nataf; Laurent Pays; Lena Hauberg-Lotte; Peter Maass; Jan H Kobarg; Firas Kobeissy; Céline Mériaux; Maxence Wisztorski; Lucia Slovinska; Juraj Blasko; Viera Cigankova; Isabelle Fournier; Michel Salzet
Journal:  Mol Cell Proteomics       Date:  2016-06-01       Impact factor: 5.911

7.  Delayed administration of a bio-engineered zinc-finger VEGF-A gene therapy is neuroprotective and attenuates allodynia following traumatic spinal cord injury.

Authors:  Sarah A Figley; Yang Liu; Spyridon K Karadimas; Kajana Satkunendrarajah; Peter Fettes; S Kaye Spratt; Gary Lee; Dale Ando; Richard Surosky; Martin Giedlin; Michael G Fehlings
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

8.  Methylprednisolone Administration Following Spinal Cord Injury Reduces Aquaporin 4 Expression and Exacerbates Edema.

Authors:  Eibar Ernesto Cabrera-Aldana; Fernando Ruelas; Cristina Aranda; Ruth Rincon-Heredia; Angelina Martínez-Cruz; Alejandro Reyes-Sánchez; Gabriel Guizar-Sahagún; Luis B Tovar-Y-Romo
Journal:  Mediators Inflamm       Date:  2017-05-10       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.